Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study
K. M. Fagerli, Elisabeth Lie, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases (2013) Vol. 73, Iss. 1, pp. 132-137
Closed Access | Times Cited: 179

Showing 26-50 of 179 citing articles:

Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence
Irini Flouri, Theodora E. Markatseli, Kyriaki Boki, et al.
The Journal of Rheumatology (2018) Vol. 45, Iss. 6, pp. 785-794
Open Access | Times Cited: 51
Tumor necrosis factor inhibitors in psoriatic arthritis
Santhi Mantravadi, Alexis Ogdie, Walter K. Kraft
Expert Review of Clinical Pharmacology (2017) Vol. 10, Iss. 8, pp. 899-910
Open Access | Times Cited: 49
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
Jeffrey R. Curtis, Paul Emery, Elaine Karis, et al.
Arthritis & Rheumatology (2020) Vol. 73, Iss. 5, pp. 759-768
Open Access | Times Cited: 43
Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
Sara Alonso, Ignacio Villa, Sabela Fernández, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 41
Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries
Brigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, et al.
Arthritis Care & Research (2021) Vol. 74, Iss. 7, pp. 1205-1218
Open Access | Times Cited: 34
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
Hidehisa Saeki, Tomotaka Mabuchi, Akihiko Asahina, et al.
The Journal of Dermatology (2022) Vol. 50, Iss. 2
Open Access | Times Cited: 25
Adalimumab with Methotrexate vs. Adalimumab Monotherapy in Psoriasis: First-Year Results of a Single-Blind Randomized Controlled Trial
G. E. van der Kraaij, Celine Busard, J. M. P. A. van den Reek, et al.
Journal of Investigative Dermatology (2022) Vol. 142, Iss. 9, pp. 2375-2383.e6
Open Access | Times Cited: 24
Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
Alan Menter, Darío Kivelevitch, Bobbak Mansouri
Biologics (2014), pp. 169-169
Open Access | Times Cited: 46
Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register
K. M. Fagerli, Lianne Kearsley‐Fleet, Kath Watson, et al.
RMD Open (2018) Vol. 4, Iss. 1, pp. e000596-e000596
Open Access | Times Cited: 46
Immunogenicity of Biologic Treatments for Psoriasis: Therapeutic Consequences and the Potential Value of Concomitant Methotrexate
Michael E. Farhangian, Steven R. Feldman
American Journal of Clinical Dermatology (2015) Vol. 16, Iss. 4, pp. 285-294
Closed Access | Times Cited: 46
Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study
Kalle Aaltonen, Arto Heinonen, Jaana Joensuu, et al.
Seminars in Arthritis and Rheumatism (2016) Vol. 46, Iss. 6, pp. 732-739
Closed Access | Times Cited: 44
Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
Sofía Ramiro, R. Landewé, Désirée van der Heijde, et al.
RMD Open (2015) Vol. 1, Iss. 1, pp. e000155-e000155
Open Access | Times Cited: 43
Eight‐Year Retention Rate of First‐Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis
Ennio Giulio Favalli, Carlo Selmi, Andrea Becciolini, et al.
Arthritis Care & Research (2016) Vol. 69, Iss. 6, pp. 867-874
Open Access | Times Cited: 40
Psoriasis and Related Disorders
A. David Burden, Brian Kirby
(2016), pp. 1-64
Closed Access | Times Cited: 40
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation
Mark Corbett, Fadi Chehadah, Mousumi Biswas, et al.
Health Technology Assessment (2017) Vol. 21, Iss. 56, pp. 1-326
Open Access | Times Cited: 40
Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris
Antonios G.A. Kolios, Nikhil Yawalkar, Mark Anliker, et al.
Dermatology (2016) Vol. 232, Iss. 4, pp. 385-406
Open Access | Times Cited: 39
Small molecule inhibitor of OGG1 blocks oxidative DNA damage repair at telomeres and potentiates methotrexate anticancer effects
Juan Miguel Baquero, Carlos Benítez‐Buelga, Varshni Rajagopal, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 30
Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences
Ennio Giulio Favalli, Irene Pontikaki, Andrea Becciolini, et al.
Clinical Rheumatology (2017) Vol. 36, Iss. 8, pp. 1747-1755
Closed Access | Times Cited: 38
Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study
Frank Behrens, Michaela Koehm, U. Arndt, et al.
The Journal of Rheumatology (2015) Vol. 43, Iss. 3, pp. 632-639
Open Access | Times Cited: 37
A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
Nikos Maniadakis, Emese Tóth, Michael Schiff, et al.
Advances in Therapy (2018) Vol. 35, Iss. 9, pp. 1333-1355
Open Access | Times Cited: 37
Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis
Peter Nash, Ennio Lubrano, Alberto Cauli, et al.
The Journal of Rheumatology (2014) Vol. 41, Iss. 11, pp. 2286-2289
Open Access | Times Cited: 35
The Effect of Comedication With a Conventional Synthetic Disease‐Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti–Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis
Michael J. Nissen, Adrian Ciurea, Jürg Bernhard, et al.
Arthritis & Rheumatology (2016) Vol. 68, Iss. 9, pp. 2141-2150
Open Access | Times Cited: 34
Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials
Bernard Combe, Frank Behrens, Neil McHugh, et al.
The Journal of Rheumatology (2016) Vol. 43, Iss. 6, pp. 1063-1067
Open Access | Times Cited: 33
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis
Corrado Campochiaro, Alessandro Tomelleri, Silvia Sartorelli, et al.
Seminars in Arthritis and Rheumatism (2020) Vol. 50, Iss. 3, pp. 509-514
Closed Access | Times Cited: 29
Smoking in spondyloarthritis: unravelling the complexities
Sizheng Steven Zhao, Nicola Goodson, Selina Robertson, et al.
Lara D. Veeken (2020) Vol. 59, Iss. 7, pp. 1472-1481
Closed Access | Times Cited: 28

Scroll to top